Dendritic Glycopolymer as Drug Delivery System for Proteasome Inhibitor Bortezomib in a Calcium Phosphate Bone Cement: First Steps Toward a Local Therapy of Osteolytic Bone Lesions

Christin Striegler, Matthias Schumacher, Christiane Effenberg, Martin Mueller, Anja Seckinger, Reinhard Schnettler, Brigitte Voit, Dirk Hose*, Michael Gelinsky, Dietmar Appelhans

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Establishment of drug delivery system (DDS) in bone substitute materials for local treatment of bone defects still requires ambitious solutions for a retarded drug release. We present two novel DDS, a weakly cationic dendritic glycopolymer and a cationic polyelectrolyte complex, composed of dendritic glycopolymer and cellulose sulfate, for the proteasome inhibitor bortezomib. Both DDS are able to induce short-term retarded release of bortezomib from calcium phosphate bone cement in comparison to a burst-release of the drug from bone cement alone. Different release parameters have been evaluated to get a first insight into the release mechanism from bone cements. In addition, biocompatibility of the calcium phosphate cement, modified with the new DDS was investigated using human mesenchymal stromal cells.
Original languageEnglish
Pages (from-to)1283-1295
Number of pages13
JournalMacromolecular Bioscience
Issue number9
Publication statusPublished - 2015
Externally publishedYes

Cite this